On February 17, the Board of Directors authorized a new share repurchase program for the purchase of up to $1B of the company’s common stock. The company’s previous share repurchase program was fully utilized prior to its December 31, 2025, expiration.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical price target lowered to $300 from $370 at BofA
- West Pharmaceutical price target lowered to $340 from $355 at UBS
- West Pharmaceutical price target raised to $315 from $310 at Deutsche Bank
- West Pharmaceutical price target lowered to $265 from $325 at Barclays
- West Pharmaceutical Services Signals HVP‑Led Growth Ahead